ClinConnect ClinConnect Logo
Search / Trial NCT07111936

Evaluating the Impact of CONNECT in a Multilingual Population

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Aug 1, 2025

Trial Information

Current as of August 24, 2025

Not yet recruiting

Keywords

Multilingual

ClinConnect Summary

This clinical trial is studying a program called CONNECT, which helps people who are getting tested for lung cancer to also quit smoking. CONNECT offers personalized support through an interactive video that talks with participants based on their answers. It also includes follow-up phone calls and text messages to connect smokers with proven tools to help them stop smoking. This study will create versions of CONNECT in Spanish and Cantonese and make it easier for participants to get nicotine replacement therapy (like patches or gum) through pharmacists. The goal is to see if these improvements help more people quit smoking.

People eligible for this study are adults aged 50 to 80 who currently smoke and are at risk for lung cancer based on their smoking history. They need to live in California and be able to understand and follow the study steps. Participants can expect to use the CONNECT program, receive follow-up support by phone or text, and have easier access to treatments that help with quitting smoking. This study is not yet recruiting, and it does not include non-smokers, people with lung cancer, or those who have serious health or cognitive issues that might make participation difficult.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 50-80 years old.
  • Current smokers defined at smoking at least one cigarette in past 7 days AND eligible for lung cancer screening (LCS) based on smoking history (\>=20 pack year history)
  • California (CA) residents
  • Able to understand and comply with study procedures for the entire length of the study.
  • Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it.
  • Exclusion Criteria:
  • Non-smokers.
  • Individuals with a diagnosis of lung cancer.
  • Individuals receiving hospice care.
  • Individuals whose providers do not think that they should participate (e.g., psychiatric illness or significant cognitive impairment that would impede the individuals ability to participate).
  • Hearing and/or vision disabilities that would prevent participants from adequately receiving treatment components such as video or telephone counseling.

About University Of California, San Francisco

The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.

Locations

San Francisco, California, United States

Patients applied

0 patients applied

Trial Officials

Judith Walsh, MD, MPH

Principal Investigator

University of California, San Francisco

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported